Celine J. Marmion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Celine J. Marmion has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Darren Martin Griffith
Department of Chemistry, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephens Green, Dublin, Ireland
18 shared publications Clodagh Mulcahy
4 shared publicationsJames P. Parker
Centre for Synthesis and Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
4 shared publications- Maria P. Morgan
Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland
4 shared publications - Ziga Ude
Centre for Synthesis and Chemical Biology, Department of Chemistry, RCSI, University of Medicine and Health Sciences, Dublin, Ireland
4 shared publications Brendan Twamley
School of Chemistry, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, Ireland
3 shared publications
Latest Publications
- Open Access
- 29 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (5) , 3427-3438
Platinum( ii ) complexes of aryl guanidine-like derivatives as potential anticancer agents: between coordination and cyclometallation
The preparation of a wide variety of Pt(II) complexes with aryl guanidines and their potential application as anticancer agents have been explored. A relatively facile synthesis of cyclometallated Pt(II) complexes of arylguanidines, preparation of Pt(II) guanidine coordination complexes and an in situ activation of platinum arylguanidine complexes with acetonitrile to create a bidentate aryl iminoguanidine Pt(II) complex were achieved. Cyclometallation methodology was extended to create a water-stable conjugate incorporating two Pt(II) ions and a diaryl bis-guanidine DNA minor groove binder. Several crystal structures were obtained confirming these complexation modes. The cyclometallated Pt(II) complexes were particularly stable to aqueous environments and were tested for Reactive Oxygen Species generation and anticancer activity in a leukaemia cancer cell line.
- 29 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (5) , 3427-3438
Open AccessPlatinum( ii ) complexes of aryl guanidine-like derivatives as potential anticancer agents: between coordination and cyclometallation
The preparation of a wide variety of Pt(II) complexes with aryl guanidines and their potential application as anticancer agents have been explored. A relatively facile synthesis of cyclometallated Pt(II) complexes of arylguanidines, preparation of Pt(II) guanidine coordination complexes and an in situ activation of platinum arylguanidine complexes with acetonitrile to create a bidentate aryl iminoguanidine Pt(II) complex were achieved. Cyclometallation methodology was extended to create a water-stable conjugate incorporating two Pt(II) ions and a diaryl bis-guanidine DNA minor groove binder. Several crystal structures were obtained confirming these complexation modes. The cyclometallated Pt(II) complexes were particularly stable to aqueous environments and were tested for Reactive Oxygen Species generation and anticancer activity in a leukaemia cancer cell line.
- Open Access
- 7 November 2023
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (2) , 533-553
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer
Purpose: The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodrug, copper-bis-belinostat (Cubisbel), in vitro and ex vivo, designed to overcome the pharmacokinetic challenges of belinostat. Methods: The in vitro metabolism of each HDACi was evaluated in human liver microsomes (HLMs) using mass spectrometry. Next, the effect of belinostat and Cubisbel on cell growth, HDAC activity, apoptosis and cell cycle was assessed in three colon cancer cell lines. Gene expression alterations induced by both HDACis were determined using RNA-Seq, followed by in silico analysis to identify master regulators (MRs) of differentially expressed genes (DEGs). The effect of both HDACis on the viability of colon cancer patient-derived tumor organoids (PDTOs) was also examined. Results: Belinostat and Cubisbel significantly reduced colon cancer cell growth mediated through HDAC inhibition and apoptosis induction. Interestingly, the in vitro half-life of Cubisbel was significantly longer than belinostat. Belinostat and its Cu derivative commonly dysregulated numerous signalling and metabolic pathways while genes downregulated by Cubisbel were potentially controlled by VEGFA, ERBB2 and DUSP2 MRs. Treatment of colon cancer PDTOs with the HDACis resulted in a significant reduction in cell viability and downregulation of stem cell and proliferation markers. Conclusions: Complexation of belinostat to Cu(II) does not alter the HDAC activity of belinostat, but instead significantly enhances its metabolic stability in vitro and targets anti-cancer pathways by perturbing key MRs in colon cancer. Complexation of HDACis to a metal ion might improve the efficacy of clinically used HDACis in patients with colon cancer.
- 7 November 2023
- Published by Springer Nature in Cellular Oncology
- Vol. 47 (2) , 533-553
Open AccessComplexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer
Purpose: The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodrug, copper-bis-belinostat (Cubisbel), in vitro and ex vivo, designed to overcome the pharmacokinetic challenges of belinostat. Methods: The in vitro metabolism of each HDACi was evaluated in human liver microsomes (HLMs) using mass spectrometry. Next, the effect of belinostat and Cubisbel on cell growth, HDAC activity, apoptosis and cell cycle was assessed in three colon cancer cell lines. Gene expression alterations induced by both HDACis were determined using RNA-Seq, followed by in silico analysis to identify master regulators (MRs) of differentially expressed genes (DEGs). The effect of both HDACis on the viability of colon cancer patient-derived tumor organoids (PDTOs) was also examined. Results: Belinostat and Cubisbel significantly reduced colon cancer cell growth mediated through HDAC inhibition and apoptosis induction. Interestingly, the in vitro half-life of Cubisbel was significantly longer than belinostat. Belinostat and its Cu derivative commonly dysregulated numerous signalling and metabolic pathways while genes downregulated by Cubisbel were potentially controlled by VEGFA, ERBB2 and DUSP2 MRs. Treatment of colon cancer PDTOs with the HDACis resulted in a significant reduction in cell viability and downregulation of stem cell and proliferation markers. Conclusions: Complexation of belinostat to Cu(II) does not alter the HDAC activity of belinostat, but instead significantly enhances its metabolic stability in vitro and targets anti-cancer pathways by perturbing key MRs in colon cancer. Complexation of HDACis to a metal ion might improve the efficacy of clinically used HDACis in patients with colon cancer.
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106449
Multi-targeted metallo-ciprofloxacin derivatives rationally designed and developed to overcome antimicrobial resistance
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106449
Multi-targeted metallo-ciprofloxacin derivatives rationally designed and developed to overcome antimicrobial resistance
- 1 June 2020
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 506, 119543
Open AccessBook review
- 1 May 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 206, 110981
Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors
- 1 May 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 206, 110981
Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors
- 4 April 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (24) , 8578-8593
A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties
Immunocompromised cancer patients are often at high risk of developing infections. Standard infection control measures are required to prevent the onset of infection but, under some circumstances, antimicrobial prophylaxis is necessary. We have developed a family of innovative metallo-antibiotics of general formula [Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene ligand and CipA stands for a derivative of the clinically used fluoroquinolone antibiotic ciprofloxacin. The X-ray crystal structure of one member from this family, [Cu(phen)(CipA)Cl] (where phen is 1,10-phenanthroline), is also reported. These complexes combine into one drug entity a Cu-N,N-framework with DNA binding and DNA oxidant properties and an antibiotic derivative with known anti-proliferative and anti-microbial activities. The complexes were all found to exhibit excellent DNA recognition with binding affinity of lead agents in the order of ∼107 M(bp)−1. Biophysical studies involving calf thymus DNA indicate the complexes intercalate or semi-intercalate DNA via the minor groove. All complexes exhibited excellent nuclease activity with DNA strand scission being mediated predominantly via superoxide and hydroxyl radicals. The complexes were found to have promising anti-proliferative effects against a human breast adenocarcinoma cell line (MCF-7) and a human prostate carcinoma cell line (DU145) with low micromolar and, in some cases, nanomolar cytotoxicities observed. Selective targeting of Gram positive bacteria was also identified by this complex class with one lead compound having an order of magnitude greater potency against Methicillin-resistant S. aureus (MRSA) as compared to the CipA ligand. Importantly, from a clinical stand point, these complexes were also found to be well tolerated in an in vivo Galleria mellonella larvae model, which has both functional and structural similarities to that of the innate immune system of mammals.
- 4 April 2019
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (24) , 8578-8593
A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties
Immunocompromised cancer patients are often at high risk of developing infections. Standard infection control measures are required to prevent the onset of infection but, under some circumstances, antimicrobial prophylaxis is necessary. We have developed a family of innovative metallo-antibiotics of general formula [Cu(N,N)(CipA)Cl] where N,N represents a phenanthrene ligand and CipA stands for a derivative of the clinically used fluoroquinolone antibiotic ciprofloxacin. The X-ray crystal structure of one member from this family, [Cu(phen)(CipA)Cl] (where phen is 1,10-phenanthroline), is also reported. These complexes combine into one drug entity a Cu-N,N-framework with DNA binding and DNA oxidant properties and an antibiotic derivative with known anti-proliferative and anti-microbial activities. The complexes were all found to exhibit excellent DNA recognition with binding affinity of lead agents in the order of ∼107 M(bp)−1. Biophysical studies involving calf thymus DNA indicate the complexes intercalate or semi-intercalate DNA via the minor groove. All complexes exhibited excellent nuclease activity with DNA strand scission being mediated predominantly via superoxide and hydroxyl radicals. The complexes were found to have promising anti-proliferative effects against a human breast adenocarcinoma cell line (MCF-7) and a human prostate carcinoma cell line (DU145) with low micromolar and, in some cases, nanomolar cytotoxicities observed. Selective targeting of Gram positive bacteria was also identified by this complex class with one lead compound having an order of magnitude greater potency against Methicillin-resistant S. aureus (MRSA) as compared to the CipA ligand. Importantly, from a clinical stand point, these complexes were also found to be well tolerated in an in vivo Galleria mellonella larvae model, which has both functional and structural similarities to that of the innate immune system of mammals.
- Top Cited Papers
- 14 January 2019
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 119 (2) , 1058-1137
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.
- 14 January 2019
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 119 (2) , 1058-1137
Top Cited PapersToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.
- 7 September 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (11) , 5058-5071
Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress
Cancer remains a global health challenge. There is an urgent need to develop innovative therapeutics that can overcome the shortcomings of existing cancer therapies. DNA enzymes involved in nucleic acid compaction and organization are an attractive cancer drug target for therapeutic exploitation. In this work a family of Cu(II) prodrugs containing suberoylanilide hydroxamic acid (SAHA), a well-established histone deacetylase inhibitor (HDACi) and clinically approved cancer drug, and phenanthrene ligands as DNA intercalative components, have been rationally developed. The complexes, of general formula [Cu(SAHA-1H)(N,N-phenanthrene)]+, exhibit excellent DNA recognition with binding affinity of lead agents in the order of ~107 M(bp)-1. Biophysical studies involving nucleic acid polymers indicate intercalative binding at both adenine-thymine (A-T) and guanine-cytosine (G-C) rich sequences but thermodynamically stable interactions are favoured in G-C tracts. The complexes mediate DNA damage by producing reactive oxygen species (ROS) with spin trapping experiments showing superoxide, the hydroxyl radical, and hydrogen peroxide play critical roles in strand scission. The agents were found to have promising anti-proliferative effects against a panel of epithelial cancers and, in two representative cell lines possessing mutated p53 (SK-OV-3 and DU145), nanomolar cytotoxicity was observed. Significantly, mechanistic experiments with the most promising candidates revealed HDAC inhibition activity was achieved over a shorter timeframe as compared to clinical standards with DNA damage-response markers identifying upregulation of both DNA synthesis and nucleotide excision repair (NER) pathways. Finally, confocal imaging and gene expression analysis show this metallodrug class to exert cytotoxic activity predominantly through an apoptotic pathway.
- 7 September 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (11) , 5058-5071
Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress
Cancer remains a global health challenge. There is an urgent need to develop innovative therapeutics that can overcome the shortcomings of existing cancer therapies. DNA enzymes involved in nucleic acid compaction and organization are an attractive cancer drug target for therapeutic exploitation. In this work a family of Cu(II) prodrugs containing suberoylanilide hydroxamic acid (SAHA), a well-established histone deacetylase inhibitor (HDACi) and clinically approved cancer drug, and phenanthrene ligands as DNA intercalative components, have been rationally developed. The complexes, of general formula [Cu(SAHA-1H)(N,N-phenanthrene)]+, exhibit excellent DNA recognition with binding affinity of lead agents in the order of ~107 M(bp)-1. Biophysical studies involving nucleic acid polymers indicate intercalative binding at both adenine-thymine (A-T) and guanine-cytosine (G-C) rich sequences but thermodynamically stable interactions are favoured in G-C tracts. The complexes mediate DNA damage by producing reactive oxygen species (ROS) with spin trapping experiments showing superoxide, the hydroxyl radical, and hydrogen peroxide play critical roles in strand scission. The agents were found to have promising anti-proliferative effects against a panel of epithelial cancers and, in two representative cell lines possessing mutated p53 (SK-OV-3 and DU145), nanomolar cytotoxicity was observed. Significantly, mechanistic experiments with the most promising candidates revealed HDAC inhibition activity was achieved over a shorter timeframe as compared to clinical standards with DNA damage-response markers identifying upregulation of both DNA synthesis and nucleotide excision repair (NER) pathways. Finally, confocal imaging and gene expression analysis show this metallodrug class to exert cytotoxic activity predominantly through an apoptotic pathway.
- 11 June 2018
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 371, 96-98
Metallo-Drugs: Development and Action of Anti-Cancer Agents, A. Sigel, H. Sigel, E. Freisinger, R.K.O. Sigel (Eds.), Vol. 18 of Metal Ions in Life Sciences [ISSN: 1559-0836, ISSN (electronic) 1868-0402], Walter de Gruyter GmbH, Berlin/Boston, 2018, 546 pp [ISBN: 978-3-11-046984-4; 978-3-11-047073-4 (electronic PDF); 978-3-11-046990-5 (electronic EPUB). Set-ISBN: 978-3-11-047074-1]. DOI https://doi.org//10.1515/9783110470734
- 11 June 2018
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 371, 96-98
Metallo-Drugs: Development and Action of Anti-Cancer Agents, A. Sigel, H. Sigel, E. Freisinger, R.K.O. Sigel (Eds.), Vol. 18 of Metal Ions in Life Sciences [ISSN: 1559-0836, ISSN (electronic) 1868-0402], Walter de Gruyter GmbH, Berlin/Boston, 2018, 546 pp [ISBN: 978-3-11-046984-4; 978-3-11-047073-4 (electronic PDF); 978-3-11-046990-5 (electronic EPUB). Set-ISBN: 978-3-11-047074-1]. DOI https://doi.org//10.1515/9783110470734
- 7 February 2017
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2017 (12) , 1596-1612
Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision?
The concept of the “magic bullet”, a medicine designed to hit a specific biological target, was pioneered by Paul Ehrlich, the father of chemotherapy, some 100 years ago. Building on Ehrlich's vision, we have endeavoured to showcase not only how targeted PtIV prodrugs may be exploited to reduce systemic toxicities associated with modern‐day chemotherapeutics, including classical PtII drugs, but also how these prodrugs may overcome resistance issues that have plagued many chemotherapeutic regimes. A summary of advances in this field over the past decade is provided, with an emphasis on PtIV prodrugs that target not only DNA but also enzymes, proteins, peptides and hormones. Synthetic strategies for accessing PtIV chemistry are also provided.
- 7 February 2017
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2017 (12) , 1596-1612
Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision?
The concept of the “magic bullet”, a medicine designed to hit a specific biological target, was pioneered by Paul Ehrlich, the father of chemotherapy, some 100 years ago. Building on Ehrlich's vision, we have endeavoured to showcase not only how targeted PtIV prodrugs may be exploited to reduce systemic toxicities associated with modern‐day chemotherapeutics, including classical PtII drugs, but also how these prodrugs may overcome resistance issues that have plagued many chemotherapeutic regimes. A summary of advances in this field over the past decade is provided, with an emphasis on PtIV prodrugs that target not only DNA but also enzymes, proteins, peptides and hormones. Synthetic strategies for accessing PtIV chemistry are also provided.